Could an immunotherapy boost chemo for sarcoma patients?
NCT ID NCT04968106
First seen Apr 26, 2026 · Last updated May 17, 2026 · Updated 4 times
Summary
This study tests whether adding the immunotherapy drug retifanlimab to standard chemotherapy before surgery can improve outcomes for people with certain soft-tissue sarcomas. About 66 adults with grade 2 or 3 sarcomas that can be surgically removed will be randomly assigned to receive either chemotherapy alone or chemotherapy plus retifanlimab. The main goal is to see if the combination leads to a better tumor response in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Curie
Paris, France
Conditions
Explore the condition pages connected to this study.